Cited by 64Neuroscience and Neuropharmacology ResearchReceptor Mechanisms and SignalingNicotinic Acetylcholine Receptors Study

Getting a Handle on Neuropharmacology by Targeting Receptor-Associated Proteins

Open access
Maher, Michael P., Matta, Jose A., Gu, Shenyan, Seierstad, Mark, Bredt, David S.·2017·Neuron

Abstract

Targeted therapy for neuropsychiatric disorders requires selective modulation of dysfunctional neuronal pathways. Receptors relevant to CNS disorders typically have associated proteins discretely expressed in specific neuronal pathways; these accessory proteins provide a new dimension for drug discovery. Recent studies show that targeting a TARP auxiliary subunit of AMPA receptors selectively modulates neuronal excitability in specific forebrain pathways relevant to epilepsy. Other medicinally important ion channels, gated by glutamate, γ-aminobutyric acid (GABA), and acetylcholine, also have associated proteins, which may be druggable. This emerging pharmacology of receptor-associated proteins provides a new approach for improving drug efficacy while mitigating side effects.

Integrity signals

Registry

Crossref · 10.1016/j.neuron.2017.10.001

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • TARPs and CNIH2/3 regulate AMPAR channel properties and cellular and synaptic trafficking.

    “TARPs and CNIH2/3 regulate AMPAR channel properties and cellular and synaptic trafficking (Straub and Tomita, 2012, Maher et al., 2017, Jacobi and von Engelhardt, 2017).”

    From The AMPA Receptor Code of Synaptic Plasticity (2018) · cites this paper as Maher et al., 2017

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Maher, M. P., Matta, J. A., Gu, S., Seierstad, M., & Bredt, D. S.
Affiliations
Johnson & Johnson (United States) (US)
Corresponding author
Bredt, David S.
Venue
Neuron
Publisher
Elsevier BV
Published
2017-12
Volume
96
Issue
5
Pages
989-1001
ISSN
0896-6273 (ISSN-L)
OpenAlex
W2775275368
Cited by
64
References
14
Citations by year
2026: 5 · 2025: 2 · 2024: 5 · 2023: 3 · 2022: 9 · 2021: 13 · 2020: 9 · 2019: 8 · 2018: 9 · 2017: 1
FWCI
0.94
Type
journal article
Language
en
Open access
Locations
  • Neuron (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
Keywords
receptor-associated protein, AMPA receptors, neuronal excitability, epilepsy, glutamate-gated ion channels, neuropsychiatric disorders, drug discovery
MeSH terms
Animals, Humans, Nerve Tissue Proteins, Neuropharmacology, Receptors, Neurotransmitter

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review